Poolberg Pharma: Building Strength Ahead of Clinical Data and Partnering Discussions

Poolberg Pharma is focused on putting itself in the strongest possible position ahead of a potentially important clinical and commercial inflection point. That means having the funding, time, and flexibility to make smart decisions rather than being forced into a deal because cash is running low.

That distinction matters. In biotech, the difference between negotiating with plenty of runway and negotiating while running on fumes can be enormous. Poolberg Pharma has generated additional funding that extends its financial runway into the second quarter of 2028. This creates breathing room, provides comfort, and most importantly, gives the company the opportunity to negotiate from a position of strength.

The next major catalyst is the upcoming topical clinical trial. If the trial produces compelling Phase 2 data, Poolberg Pharma expects that data to substantially strengthen the case for prospective partners to bring the program in-house. The opportunity is significant, the interest to date has been encouraging, and positive data could open the door to meaningful upfront payments, milestones, and royalty streams.

Why Financial Runway Changes Everything for Poolberg Pharma

There is a simple reality in drug development: companies do not want to negotiate when they have no alternatives. If a company is close to exhausting its cash, it may have to accept the first deal put in front of it, even if that deal does not properly reflect the potential value of the asset.

Poolberg Pharma has worked to avoid that scenario. The additional funding provides runway into Q2 2028, allowing the company to progress its plans without the immediate pressure of a shrinking cash balance. That matters because it gives management more choice.

With greater financial flexibility, Poolberg Pharma can take the time to assess opportunities carefully, compare potential counterparties, and focus on securing terms that make sense for both the program and shareholders. Rather than pursuing a transaction out of necessity, the company can pursue one when the evidence, timing, and economics are right.

Runway creates optionality. Optionality is valuable because it allows a company to remain disciplined. It can wait for important data, evaluate the level of industry interest after that data arrives, and negotiate with a clearer view of the program’s potential.

The Upcoming Topical Trial Is the Key Near-Term Inflection Point

The central near-term objective for Poolberg Pharma is the generation of data from its upcoming topical clinical trial. Clinical data is the foundation of value creation in a development-stage pharmaceutical company. It can either reduce uncertainty around a program or reveal the need for further work.

For a prospective pharmaceutical partner, strong Phase 2 results can be especially meaningful. Positive, compelling data can help de-risk a program by providing clearer evidence of its potential. The more risk that has been removed before a partner steps in, the more attractive the program may become.

This is why Poolberg Pharma is focused on reaching the data milestone before entering deeper partnering negotiations. The company is not simply looking to make a deal. It is looking to negotiate after it has added an important body of clinical evidence that could increase the program’s value.

The logic is straightforward:

• Complete the upcoming topical clinical trial.
• Generate and assess the clinical data.
• Use compelling Phase 2 results to further de-risk the program.
• Engage in deeper negotiations with interested industry partners.
• Seek terms that reflect the program’s potential and serve shareholders well.

Poolberg Pharma has indicated that there is already good interest in the program. Data has the potential to turn that interest into more substantial commercial discussions.

De-Risking a Program Can Drive Partner Interest

The pharmaceutical industry is built around risk and reward. A partner that brings an early-stage asset in-house takes on development, regulatory, commercial, and financial risk. Naturally, the level of risk influences what that partner is willing to pay and how a deal is structured.

For Poolberg Pharma, compelling Phase 2 data from the topical trial could materially shift that equation. If the results support the potential of the program, they may give potential partners a stronger basis for evaluating the opportunity and deciding whether to pursue it.

The program is aimed at what Poolberg Pharma describes as a multi-billion-dollar opportunity. In that context, evidence that de-risks the asset may be highly valuable. Pharmaceutical companies can write significant checks when a program has attractive market potential and the clinical evidence supports a credible path forward.

That does not mean that any outcome is guaranteed. Deal terms always depend on the data, the level of competitive interest, the preferences of the parties involved, and the final transaction structure. But Poolberg Pharma’s approach is designed to ensure that the company reaches that negotiating table with the strongest possible hand.

Negotiating From Strength Rather Than Necessity

There is a major difference between having to do a deal and choosing to do a deal.

When a company is under financial pressure, counterparties know it. That can reduce leverage, narrow the range of potential terms, and create pressure to move quickly. A healthy balance sheet changes the dynamic. It means the company has time to negotiate, time to consider alternatives, and time to focus on the long-term value of the program.

For Poolberg Pharma, the funding runway into Q2 2028 is therefore more than a balance sheet figure. It supports the broader partnering strategy. It allows the company to wait for clinical data before committing to deeper discussions and helps ensure that negotiations are driven by evidence rather than urgency.

This is particularly relevant when a program may attract interest from multiple parties. Strong data can increase attention. A company with adequate cash can then assess the available opportunities and seek the best possible fit, rather than feeling compelled to accept an early proposal.

The objective is not simply to complete a transaction. The objective is to secure the best deal possible for Poolberg Pharma and its shareholders.

What a Potential Partnership Could Include

If the upcoming trial delivers the positive data Poolberg Pharma hopes to see, the company believes there could be a strong case for meaningful financial consideration from a partner seeking access to the program.

Any partnership structure will depend on the eventual negotiation, but the potential components discussed include:

• Upfront payments: Initial payments made when a partner obtains access to the program.
• Development and commercial milestones: Further payments linked to agreed achievements over time.
• Royalties: Payments that may be associated with future commercial performance, depending on the terms of a deal.

These elements are important because they can recognize value at different points in the life of a program. An upfront payment may reflect the immediate value of the data and opportunity. Milestones may reward progress through later development or other agreed events. Royalties can provide exposure to future commercial success.

Of course, there is no single standard structure. The balance between upfront consideration, milestones, and royalties can vary widely. That is exactly why negotiating leverage matters. Poolberg Pharma’s financial position and expected clinical catalyst are intended to support a more robust discussion around the full value of the asset.

Interest Today, Evidence Tomorrow

Poolberg Pharma has already seen a good level of interest. That is an encouraging starting point, but clinical data remains the critical piece that can add substance to the conversation.

Interest can be based on the size of the opportunity, the type of program, and the strategic relevance for a potential partner. Compelling clinical data can provide the additional support needed for a counterparty to make a more concrete commitment.

The company’s plan is therefore practical and disciplined. Generate the data first. Once that evidence is in hand, begin deeper negotiations. With funding in place and runway extending to Q2 2028, Poolberg Pharma can approach those discussions without being backed into a corner.

This is a valuable position to be in. The company is preparing for a major data event while maintaining the flexibility to consider partnering opportunities on terms that reflect the potential of the program.

A Clear Focus on Long-Term Value

Poolberg Pharma is pursuing a strategy built around three connected ideas: fund the business adequately, generate compelling clinical evidence, and use that evidence to negotiate from strength.

Each element supports the next. Funding gives the company time. Time allows Poolberg Pharma to reach the clinical data milestone without the pressure to accept a premature transaction. Positive data could further de-risk the program. Reduced risk, in turn, may support more attractive partnering terms.

For shareholders, this approach is about protecting and maximizing potential value. It is about ensuring that a potentially significant opportunity is not negotiated away simply because a company lacks the financial runway to wait for the right moment.

Poolberg Pharma has set out a clear path. The next major step is the topical clinical trial and the data it produces. If that data is compelling, the company expects partnering discussions to become considerably more meaningful. With a healthy balance sheet and runway into Q2 2028, Poolberg Pharma intends to be ready for that moment.